Sept 29 (Reuters) - Actinogen Medical Ltd ACW.AX
* Will communicate with FDA and if questions cannot be resolved in time, will not be able to recruit patients in phase ii trial by end of 2016
* Received feedback from FDA with further questions around potential safety surveillance of drug xanamem Source text for Eikon: ID:nASX3Qh0ZD Further company coverage: ACW.AX